Orthopedic Oncology

Understanding Your Diagnosis: Biology and Imaging

At a Glance

Chondrosarcoma is a cartilage-producing bone cancer diagnosed using MRI and PET/CT scans. Doctors look for specific imaging signs, like endosteal scalloping and high SUVmax, to distinguish it from benign tumors. Biopsies must be carefully planned by your surgeon to prevent cancer spread.

Chondrosarcoma is a unique cancer because it doesn’t just grow on the bone; it is made of cells that produce cartilage (the tough, flexible tissue found in joints) inside the bone ^[1]. Understanding the biology and the specialized imaging used to find it can help you make sense of your diagnosis and the “borderline” nature of many cartilaginous tumors.

The Biology: How it Develops

At its core, chondrosarcoma is a “cartilage-forming” tumor ^[1]. Most cases start with a genetic “glitch” in the bone’s internal environment.

IDH Mutations: In about 50% to 70% of conventional chondrosarcomas, researchers have found mutations in genes called IDH1 or IDH2 ^[2]^[3]. These mutations cause the cell to produce an abnormal molecule that blocks the cell’s ability to mature, causing them to stay in a primitive, rapidly dividing state ^[2].
Cartilage Matrix: Unlike other cancers that form soft masses, these tumors create a “matrix” of cartilage. This cartilage often hardens or calcifies over time, which creates the distinctive “popcorn” or “ring-and-arc” appearance seen on X-rays ^[4].

The Great Challenge: Enchondroma vs. Low-Grade Tumors

One of the most difficult tasks for your medical team is distinguishing between a benign enchondroma (a non-cancerous cartilage growth) and a low-grade tumor (like Atypical Cartilaginous Tumor (ACT)) ^[5]^[6].

Under a microscope, these two can look nearly identical ^[7]. Because of this, doctors rely heavily on “clinical behavior” and imaging:

Pain: A true enchondroma is usually painless and found by accident. A chondrosarcoma is more likely to cause a deep, aching pain ^[7].
Endosteal Scalloping: This is a key term in radiology reports. It refers to the tumor “eating away” at the inner lining of the hard outer bone ^[8]. If the tumor has eroded more than two-thirds of the bone’s thickness, it is much more likely to be a low-grade cancer than a benign growth ^[9]^[10].

The Role of Advanced Imaging

Because a biopsy only takes a tiny sample, doctors use multimodality imaging to see the “big picture” of the tumor.

MRI: The Gold Standard for Structure

MRI (Magnetic Resonance Imaging) is the best tool for seeing the tumor’s size and how it interacts with the bone ^[11]. Doctors look for a High T2 Signal, which indicates a high water content typical of cartilage ^[4]. They also check for soft tissue extension—whether the tumor has broken out of the bone and moved into nearby muscle ^[7].

PET/CT and SUVmax: The Metabolism Map

A PET/CT scan measures how much “sugar” (glucose) the tumor is consuming. This is measured by a value called SUVmax (Maximum Standardized Uptake Value) ^[12].

Low SUVmax: Generally suggests a benign enchondroma or a very low-grade tumor ^[12]^[13].
High SUVmax: A higher value suggests a more aggressive, higher-grade chondrosarcoma ^[14]^[13].

The Role and Limits of Biopsy

A biopsy (taking a tissue sample) is often used to confirm the diagnosis, but it has a major limitation called tumor heterogeneity ^[15]. This means a tumor might be low-grade in one spot but higher-grade in another ^[16]. If the needle hits the low-grade spot, the higher-grade part could be missed.

To safeguard against this, surgeons rely heavily on multimodality imaging, like PET/CT, to specifically target the biopsy needle toward the most metabolically active-looking (highest SUVmax) part of the tumor ^[17]^[18]. If clinical suspicion remains high despite a low-grade biopsy, they may treat the tumor based on its imaging features ^[16].

Crucial Note on Biopsies: It is a cardinal rule of sarcoma care that the biopsy should be performed (or directly supervised) by the orthopedic oncology team who will do your definitive surgery. The biopsy needle creates a “tract” where cancer cells can seed. To prevent local recurrence, your surgeon must completely remove this exact needle tract during the final surgery ^[19].

Common questions in this guide

What is the difference between an enchondroma and chondrosarcoma?

An enchondroma is a benign, non-cancerous cartilage growth that is typically painless and found by accident. A chondrosarcoma is a cancerous cartilage tumor that often causes a deep, aching pain and shows different features on imaging scans.

What does endosteal scalloping mean on my MRI report?

Endosteal scalloping is a radiology term that means the tumor is eroding or 'eating away' at the inner lining of the hard outer bone. If the tumor has eroded a significant portion of the bone's thickness, it strongly suggests a low-grade cancer rather than a benign growth.

Why is SUVmax important on a PET/CT scan for bone tumors?

SUVmax measures how much glucose, or energy, a tumor is consuming. A low SUVmax typically points to a benign or very low-grade tumor, while a high SUVmax suggests a more aggressive, higher-grade chondrosarcoma.

Why does my orthopedic oncologist need to perform my biopsy?

A biopsy needle creates a microscopic tract where cancer cells can accidentally spread. The orthopedic oncologist who will perform your final surgery must plan and supervise the biopsy so they can safely remove that exact needle tract during your operation.

Curated prompts to bring to your next appointment.

1.Does my MRI show signs of 'endosteal scalloping,' and if so, how much of the bone's thickness is affected?
2.What was the SUVmax on my PET/CT scan, and does that value lean more toward a benign or malignant diagnosis?
3.Given that chondrosarcomas can be heterogeneous, how did you choose the specific site for my biopsy to ensure we didn't miss a higher-grade area?
4.Did the molecular testing of my tumor reveal an IDH1 or IDH2 mutation?
5.Will the doctor performing the biopsy also be the orthopedic oncologist performing my final surgery to ensure the needle tract is removed?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Chondrosarcoma of the spine-a case report.
Simon S, Resch H, Lomoschitz F, et al.
Wiener medizinische Wochenschrift (1946) 2023; (173(13-14)):334-338 doi:10.1007/s10354-021-00897-9.
PMID: 35119543
2
Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG, Grenert JP, Horvai A
Archives of pathology & laboratory medicine 2021; (145(8)):1009-1017 doi:10.5858/arpa.2020-0379-OA.
PMID: 33147331
3
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S, Fritchie K, Wei S, et al.
Human pathology 2017; (65()):239-246 doi:10.1016/j.humpath.2017.05.015.
PMID: 28552826
4
Differentiation between Chondrosarcoma and Synovial Chondromatosis of the Temporomandibular Joint Using CT and MR Imaging.
Jang BG, Huh KH, Yeom HG, et al.
AJNR. American journal of neuroradiology 2023; (44(10)):1176-1183 doi:10.3174/ajnr.A7980.
PMID: 37652584
5
Differential Diagnosis of Cartilaginous Lesions of Bone.
Suster D, Hung YP, Nielsen GP
Archives of pathology & laboratory medicine 2020; (144(1)):71-82 doi:10.5858/arpa.2019-0441-RA.
PMID: 31877083
6
A pragmatic approach to the imaging and follow-up of solitary central cartilage tumours of the proximal humerus and knee.
Patel A, Davies AM, Botchu R, James S
Clinical radiology 2019; (74(7)):517-526 doi:10.1016/j.crad.2019.01.025.
PMID: 30827492
7
Chondroid Tumors as Incidental Findings and Differential Diagnosis between Enchondromas and Low-grade Chondrosarcomas.
Afonso PD, Isaac A, Villagrán JM
Seminars in musculoskeletal radiology 2019; (23(1)):3-18 doi:10.1055/s-0038-1675550.
PMID: 30699449
8
Risk factors for local recurrence from atypical cartilaginous tumour and enchondroma of the long bones.
Errani C, Tsukamoto S, Ciani G, et al.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologie 2017; (27(6)):805-811 doi:10.1007/s00590-017-1970-4.
PMID: 28501961
9
What are the differentiating clinical and MRI-features of enchondromas from low-grade chondrosarcomas?
Douis H, Parry M, Vaiyapuri S, Davies AM
European radiology 2018; (28(1)):398-409 doi:10.1007/s00330-017-4947-0.
PMID: 28695356
10
The role of imaging in differentiating low-grade and high-grade central chondral tumours.
Sharif B, Lindsay D, Saifuddin A
European journal of radiology 2021; (137()):109579 doi:10.1016/j.ejrad.2021.109579.
PMID: 33578088
11
Imaging features of chondrosarcoma of the temporomandibular joint: report of nine cases and literature review.
Jang BG, Huh KH, Kang JH, et al.
Clinical radiology 2020; (75(11)):878.e1-878.e12 doi:10.1016/j.crad.2020.07.016.
PMID: 32843140
12
Quantitative Bone SPECT/CT of Central Cartilaginous Bone Tumors: Relationship between SUVmax and Radiodensity in Hounsfield Unit.
Yoon H, Lee SK, Kim JY, Joo MW
Cancers 2024; (16(11)) doi:10.3390/cancers16111968.
PMID: 38893090
13
The utility of 18F-FDG PET and PET/CT in the diagnosis and staging of chondrosarcoma: a meta-analysis.
Zhang Q, Xi Y, Li D, et al.
Journal of orthopaedic surgery and research 2020; (15(1)):229 doi:10.1186/s13018-020-01748-w.
PMID: 32571371
14
F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
Subhawong TK, Winn A, Shemesh SS, Pretell-Mazzini J
Skeletal radiology 2017; (46(9)):1233-1239 doi:10.1007/s00256-017-2685-7.
PMID: 28608242
15
The role of grade in local recurrence and the disease-specific survival in chondrosarcomas.
Laitinen MK, Stevenson JD, Parry MC, et al.
The bone & joint journal 2018; (100-B(5)):662-666 doi:10.1302/0301-620X.100B5.BJJ-2017-1243.R1.
PMID: 29701096
16
Mosaic-pattern dedifferentiation in liposarcoma and chondrosarcoma: imaging features of an uncommon form of dedifferentiation.
Taylor K, Kransdorf MJ, Schwartz AJ, et al.
Skeletal radiology 2018; (47(6)):877-882 doi:10.1007/s00256-017-2866-4.
PMID: 29362843
17
Exact radiological-pathological correlation of chondrosarcomas using a patient-specific 3D mold.
Lejoly M, Van Den Berghe T, Creytens D, et al.
Skeletal radiology 2025; (54(10)):2179-2190 doi:10.1007/s00256-025-04942-1.
PMID: 40358730
18
FDG PET/CT and MRI Findings of Extraskeletal Myxoid Chondrosarcoma Showing a Nonmyxoid Cellular Variant.
Hirasawa M, Kikuchi Y, Sato K, et al.
Clinical nuclear medicine 2024; (49(5)):434-437 doi:10.1097/RLU.0000000000005146.
PMID: 38557577
19
Mesenchymal Chondrosarcoma of the Mandible, a Big Dilemma: Report of a Rare Case in Mesenchymal Chondrosarcoma of the Mandible-Report of a Case With Discussion of Diagnostic and Therapeutic Dilemmas.
Karimi A, Derakhshan S, Mosavat F, et al.
Case reports in dentistry 2024; (2024()):8884697 doi:10.1155/2024/8884697.
PMID: 39503009

This page explains chondrosarcoma biology and imaging for educational purposes. Always discuss your specific scan results and biopsy options with your orthopedic oncologist.

Get notified when new evidence is published on Chondrosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents